Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.
In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim